BridgeBio Pharma Says Drug Reduced Death, Hospitalization in Cardiomyopathy Patients After 1 Month

MT Newswires Live
Sep 29

BridgeBio Pharma (BBIO) said Sunday that its drug acoramidis reduced mortality and hospitalizations within the first month of treatment in patients with transthyretin amyloid cardiomyopathy.

The company said patients treated with the drug showed "numerically fewer" cumulative events compared to placebo.

The drug also reduced hazards by 49% after 30 months and by 45% after 42 months compared to a placebo, the company said.

The illness, caused by a buildup of proteins in the heart, can lead to death and hospitalization.

Acoramidis is approved as Attruby by the US Food and Drug Administration and as Beyonttra by European, Japanese, and the UK authorities for stabilization of transthyretin amyloid cardiomyopathy, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10